Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2018 | Cardio-oncology: a new medical field

Alex Lyon • 6 Apr 2018
BSH 2018
General

With the increasing life expectancy of cancer patients, the long-term consequences of cancer therapy are becoming an increasing issue. Anthracycline-induced heart failure is a classic example of an adverse cardiovascular effect of cancer therapy. Here, Alex Lyon, MA, BM BCh, PhD, FRCP, from Imperial College, London, UK, discusses the recent development of cardio-oncology as a recognized sub-specialty dedicated to the prevention, identification and treatment of cardiovascular complications in patients receiving cancer therapy. This interview was recorded at the British Society for Hematology (BSH) 2018 Annual Scientific Meeting, Liverpool, UK.

More from Alex Lyon

Cardiovascular health in patients with MPNs: risk stratification and management strategies
4:31
Cardiovascular health in patients with MPNs: risk stratification and management strategies
Alex Lyon • 28 Jun 2025
Prevention strategies for patients with MPNs at high risk of cardiovascular disease
1:38
Prevention strategies for patients with MPNs at high risk of cardiovascular disease
Alex Lyon • 28 Jun 2025
Understanding drug-drug interactions in patients receiving both cardiac and oncology treatments
1:27
Understanding drug-drug interactions in patients receiving both cardiac and oncology treatments
Alex Lyon • 28 Jun 2025
Key papers in cardio-oncology from 2023 of relevance to hematologists
6:38
Key papers in cardio-oncology from 2023 of relevance to hematologists
Alex Lyon • 25 Apr 2024

Related Videos

The ethical challenges of AI in hematology: patient communication, trust and regulation
3:12
The ethical challenges of AI in hematology: patient communication, trust and regulation
Adrián Mosquera Orgueira • 24 Sep 2026
The future of AI in hematology: personalized medicine, opportunities and risks
2:30
The future of AI in hematology: personalized medicine, opportunities and risks
Adrián Mosquera Orgueira • 24 Sep 2026
The multi-system impacts of CHIP and its link to subspecialties within internal medicine
5:18
The multi-system impacts of CHIP and its link to subspecialties within internal medicine
Shyam Patel • 13 Oct 2026
The scientific and clinical implications of therapy-related CHIP in oncology
2:43
The scientific and clinical implications of therapy-related CHIP in oncology
Shyam Patel • 13 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals